Aging, AI, and the Uneven Road to Longevity Medicine

Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of longevity medicine.

А couple of weeks ago, our co-founder Andrii Buvailo, PhD outlined three main conclusions about the modern aging research landscape, drawing on discussions from ARDD2025 in Copenhagen, where he was present. Among other ideas, he makes a point that the recent conversion of aging research from theoretical into practical realm is heavily driven by AI, which is enabling better biological modeling, sharper insight into aging, and new ideas for confronting humanity’s core limitation.

There are other speakers highlighting the promises of AI for solving aging. Anthropic CEO Dario Amodei said at 2025 WEF that if AI dramatically accelerates biological research, doubling the human lifespan by around 2030 isn’t unrealistic because it could compress “100 years of progress” into 5–10 years. Such claims are controversial, but they reflect a real trend: AI is impacting both basic geroscience and emerging longevity medicine. Before delving deeper into the intersection of AI and longevity, let’s overview the history of this field before machines came.

In this article: Nothing Lasts Forever — Aging Hallmarks & AI — Seeking Philosopher’s Stone — To Practical Longevity